GoodRx to Offer Qsymia for $149

Investing.com — GoodRx shares rose 1.5% in premarket trading Tuesday after the healthcare company announced it will provide a 30-day supply of oral weight management drug Qsymia for $149.

However, the stock later lost the gains, trading 0.5% lower after the market opened.

According to a press release, "QSYMIA is available for a low cash price in more than 70,000 retail pharmacy locations nationwide exclusively via GoodRx."

This decision reflects GoodRx’s efforts to expand in the weight-loss sector and to focus on making brand-name medications more affordable for millions of people.

With over two in five U.S. adults affected by obesity, the demand for effective weight-loss drugs has surged, despite many facing barriers related to high costs and restricted insurance coverage.

Through its collaboration with Vivus, the developer of Qsymia, GoodRx aims to assist "those struggling with weight and obesity in finding more affordable ways to access the treatments they need."

Qsymia, an oral medication that combines phentermine and topiramate, is designed to reduce hunger and cravings. Studies have shown that it can aid patients in losing and maintaining weight when combined with diet and exercise. Unlike injectables, which are often deemed inconvenient, Qsymia presents a simpler, daily pill option.

As part of this initiative, anyone with a valid prescription can purchase a 30-day supply of Qsymia at the cash price of $149 through GoodRx, regardless of insurance.

"Obesity medications are life-changing for millions of Americans, but accessibility and affordability often hinder many consumers," stated Dorothy Gemmell, Chief Commercial Officer at GoodRx.

"Through this partnership, we’re making strides in providing these essential medications to those in need, and improving access to a treatment that not only supports weight loss but is also linked to better outcomes for other costly chronic diseases."